Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 89

Similar articles for PubMed (Select 18481171)

1.

The BARD1 Cys557Ser polymorphism and breast cancer risk: an Australian case-control and family analysis.

Johnatty SE, Beesley J, Chen X, Hopper JL, Southey MC, Giles GG, Goldgar DE, Chenevix-Trench G, Spurdle AB; Australian Ovarian Cancer Study Group; Kathleen Cuningham Consortium for Research in Familial Breast Cancer.

Breast Cancer Res Treat. 2009 May;115(1):145-50. doi: 10.1007/s10549-008-0045-y. Epub 2008 May 15.

PMID:
18481171
2.

BARD1 variants are not associated with breast cancer risk in Australian familial breast cancer.

Gorringe KL, Choong DY, Visvader JE, Lindeman GJ, Campbell IG.

Breast Cancer Res Treat. 2008 Oct;111(3):505-9. Epub 2007 Oct 31.

PMID:
17972171
3.

The BARD1 Cys557Ser variant and breast cancer risk in Iceland.

Stacey SN, Sulem P, Johannsson OT, Helgason A, Gudmundsson J, Kostic JP, Kristjansson K, Jonsdottir T, Sigurdsson H, Hrafnkelsson J, Johannsson J, Sveinsson T, Myrdal G, Grimsson HN, Bergthorsson JT, Amundadottir LT, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K.

PLoS Med. 2006 Jul;3(7):e217.

4.

The BARD1 Cys557Ser variant and risk of familial breast cancer in a South-American population.

Gonzalez-Hormazabal P, Reyes JM, Blanco R, Bravo T, Carrera I, Peralta O, Gomez F, Waugh E, Margarit S, Ibañez G, Santos JL, Jara L.

Mol Biol Rep. 2012 Aug;39(8):8091-8. doi: 10.1007/s11033-012-1656-2. Epub 2012 Apr 28.

PMID:
22544576
5.

Common non-synonymous polymorphisms in the BRCA1 Associated RING Domain (BARD1) gene are associated with breast cancer susceptibility: a case-control analysis.

Huo X, Hu Z, Zhai X, Wang Y, Wang S, Wang X, Qin J, Chen W, Jin G, Liu J, Gao J, Wei Q, Wang X, Shen H.

Breast Cancer Res Treat. 2007 May;102(3):329-37. Epub 2006 Sep 21.

PMID:
17028982
6.

Nordic collaborative study of the BARD1 Cys557Ser allele in 3956 patients with cancer: enrichment in familial BRCA1/BRCA2 mutation-negative breast cancer but not in other malignancies.

Karppinen SM, Barkardottir RB, Backenhorn K, Sydenham T, Syrjäkoski K, Schleutker J, Ikonen T, Pylkäs K, Rapakko K, Erkko H, Johannesdottir G, Gerdes AM, Thomassen M, Agnarsson BA, Grip M, Kallioniemi A, Kere J, Aaltonen LA, Arason A, Møller P, Kruse TA, Borg A, Winqvist R.

J Med Genet. 2006 Nov;43(11):856-62. Epub 2006 Jul 6.

7.

BARD1 variants Cys557Ser and Val507Met in breast cancer predisposition.

Vahteristo P, Syrjäkoski K, Heikkinen T, Eerola H, Aittomäki K, von Smitten K, Holli K, Blomqvist C, Kallioniemi OP, Nevanlinna H.

Eur J Hum Genet. 2006 Feb;14(2):167-72.

8.

BARD1 and breast cancer in Poland.

Jakubowska A, Cybulski C, Szymańska A, Huzarski T, Byrski T, Gronwald J, Debniak T, Górski B, Kowalska E, Narod SA, Lubiński J.

Breast Cancer Res Treat. 2008 Jan;107(1):119-22. Epub 2007 Feb 27.

PMID:
17333333
9.

Lack of association between BARD1 Cys557Ser variant and breast cancer risk: a meta-analysis of 11,870 cases and 7,687 controls.

Ding DP, Zhang Y, Ma WL, He XF, Wang W, Yu HL, Guo YB, Zheng WL.

J Cancer Res Clin Oncol. 2011 Oct;137(10):1463-8. doi: 10.1007/s00432-011-1006-0. Epub 2011 Aug 2.

PMID:
21809034
10.

Mutational analysis of BARD1 in familial breast cancer patients in Japan.

Ishitobi M, Miyoshi Y, Hasegawa S, Egawa C, Tamaki Y, Monden M, Noguchi S.

Cancer Lett. 2003 Oct 8;200(1):1-7.

PMID:
14550946
11.

Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis.

Wu JY, Vlastos AT, Pelte MF, Caligo MA, Bianco A, Krause KH, Laurent GJ, Irminger-Finger I.

Int J Cancer. 2006 Mar 1;118(5):1215-26.

PMID:
16152612
13.

Genetic sequence variations of BRCA1-interacting genes AURKA, BAP1, BARD1 and DHX9 in French Canadian families with high risk of breast cancer.

Guénard F, Labrie Y, Ouellette G, Beauparlant CJ, Durocher F; INHERIT BRCAs.

J Hum Genet. 2009 Mar;54(3):152-61. doi: 10.1038/jhg.2009.6. Epub 2009 Feb 6.

PMID:
19197335
14.

Mutation screening of the BARD1 gene: evidence for involvement of the Cys557Ser allele in hereditary susceptibility to breast cancer.

Karppinen SM, Heikkinen K, Rapakko K, Winqvist R.

J Med Genet. 2004 Sep;41(9):e114. No abstract available.

15.

Oncogenic BARD1 isoforms expressed in gynecological cancers.

Li L, Ryser S, Dizin E, Pils D, Krainer M, Jefford CE, Bertoni F, Zeillinger R, Irminger-Finger I.

Cancer Res. 2007 Dec 15;67(24):11876-85.

16.

Is there more to BARD1 than BRCA1?

Irminger-Finger I, Jefford CE.

Nat Rev Cancer. 2006 May;6(5):382-91. Review.

PMID:
16633366
17.

The RAD51D E233G variant and breast cancer risk: population-based and clinic-based family studies of Australian women.

Dowty JG, Lose F, Jenkins MA, Chang JH, Chen X, Beesley J, Dite GS, Southey MC, Byrnes GB, Tesoriero A, Giles GG, Hopper JL, Spurdle AB; kConFab Investigators; Australian Breast Cancer Family Study (ABCFS).

Breast Cancer Res Treat. 2008 Nov;112(1):35-9. Epub 2007 Dec 4.

PMID:
18058226
18.
19.

Identification of novel alternatively spliced BRCA1-associated RING domain (BARD1) messenger RNAs in human peripheral blood lymphocytes and in sporadic breast cancer tissues.

Lombardi G, Falaschi E, Di Cristofano C, Naccarato AG, Sensi E, Aretini P, Roncella M, Bevilacqua G, Caligo MA.

Genes Chromosomes Cancer. 2007 Sep;46(9):791-5.

PMID:
17497650
20.

BARD1 homozygous deletion, a possible alternative to BRCA1 mutation in basal breast cancer.

Sabatier R, Adélaïde J, Finetti P, Ferrari A, Huiart L, Sobol H, Chaffanet M, Birnbaum D, Bertucci F.

Genes Chromosomes Cancer. 2010 Dec;49(12):1143-51. doi: 10.1002/gcc.20822.

PMID:
20842729
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk